Canada 1994* | Europe 1995† | Australia 1998‡ | Switzerland | Belgium 2003¶ | ||
2001§ | 2006§ | |||||
Salbutamol (%) | ||||||
All patients | 85 | 61 | 7 | 55 | 18 | NA |
Sometimes | NA | NA | 69 | 42 | 72 | NA |
Only high risk patients | NA | 34 | 12 | 1 | 3 | NA |
Never | NA | 5 | 9 | 2 | 7 | 11 |
Steroids (%) | ||||||
All patients | 28 | 11 | 1 | 27 | 7 | 2 |
Sometimes | NA | NA | 35 | 52 | 45 | 32 |
Only high risk patients | NA | 69 | 22 | 6 | 8 | 20 |
Never | NA | 19 | 38 | 15 | 40 | 46 |
Ribavirin (%) | ||||||
All patients | 6 | 0 | 0 | 0 | 0 | NA |
Sometimes | NA | NA | 1 | 2 | 1 | NA |
Only high risk patients | NA | 57 | 11 | 6 | 8 | NA |
Never | NA | 43 | 83 | 90 | 91 | NA |
*Retrospective study in hospitals.18 †Questionnaire survey with specialised paediatric infectious disease physicians.17 ‡Questionnaire survey with paediatricians—response rate 62%.21 §Current study. ¶Questionnaire survey with paediatricians—response rate 40%. NA, not available.28